

# Risperdal Plaintiffs Gain Leverage in Wake of \$70M Verdict

Friday, July 8, 2016

Jim Heller, chair of Cozen O'Connor's Products Liability practice, discusses the Risperdal mass tort in the *Legal Intelligencer*. A Philadelphia jury on July 1 returned the award against Janssen and in favor of a boy who claimed the antipsychotic drug, Risperdal, led to excess growth of breast tissue. The plaintiffs in *A.Y. v. Janssen Pharmaceuticals* had argued that the company knew the medication caused the condition but failed to properly inform the medical community, emphasizing potential profits for the drug over its safety. Attorneys noted that an appeal is coming, and several questioned whether the full amount will survive a remittitur challenge. "I'd rather be the appellee than appellant ... but I don't see how they can substantiate a verdict for those damages," said Jim.

To read the article, click [here](#).



**James H. Heller**

Co-Chair, Commercial Litigation Department  
Chair, Product Liability

jimheller@cozen.com  
Phone (215) 665-2189  
Fax (215) 701-2189

#### Related Practice Areas

- Product Liability